Craft

ACADIA Pharmaceuticals

Stock Price

$27

2023-08-31

Market Capitalization

$4.4 B

2023-08-31

Revenue

$517.2 M

FY, 2022

ACADIA Pharmaceuticals Summary

Company Summary

Overview
ACADIA Pharmaceuticals (formerly known as Receptor Technologies) is a biopharmaceutical company focused on the development and commercialization of medicines that address medical needs in central nervous system (CNS) disorders. Its main product is NUPLAZID that is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). The company also works on other solutions for dementia-related psychosis, Rett syndrome, negative symptoms of schizophrenia, etc.
Type
Public
Status
Active
Founded
1993
HQ
San Diego, CA, US | view all locations
Website
https://www.acadia-pharm.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Stephen R. Davis

    Stephen R. Davis, Chief Executive Officer, Director

  • Serge Stankovic
  • Austin D. Kim

    Austin D. Kim, Executive Vice President, General Counsel and Secretary

  • Mark Schneyer

    Mark Schneyer, Executive Vice President, Chief Financial Officer

Operating MetricsView all

Products Marketed

1

FY, 2021

Patents (US)

47
30.6%

FY, 2021

Office Space Leased, sq. ft.

123K

FY, 2021

LocationsView all

2 locations detected

  • San Diego, CA HQ

    United States

    12830 El Camino Real #400

  • Princeton, NJ

    United States

    502 Carnegie Center #300

ACADIA Pharmaceuticals Financials

Summary Financials

Revenue (Q2, 2023)
$165.2M
Gross profit (Q2, 2023)
$157.8M
Net income (Q2, 2023)
$1.1M
Cash (Q2, 2023)
$107.9M
EBIT (Q2, 2023)
$3.0M
Enterprise value
$4.4B

Footer menu